Journal Logo

PLATELET GLYCOPROTEIN (GP IIB/IIIA) GENE POLYMORPHISM AS A RISK FACTOR FOR ISCHEMIC CEREBRO VASCULAR STROKE

PB2436

Abdelhamid, Saad D.A.E.1; Attia, F. M.1; Hosny, A. O.2; Elsamahy, Abdelfatah M.2; Ibrahiem, G. A.1; Abdelhamid, M. A.S.3

doi: 10.1097/01.HS9.0000568204.78420.89
Publication Only: Thrombosis and vascular biology - Biology & translational research
Free

1Laboratory Hematology; Clinical Pathology Department

2NEUROPSYCHIATRH

3Community Medicine, Faculty of medicine, Suez Canal University, Ismailia, Egypt, Ismailia, Egypt

Back to Top | Article Outline

Background:

Recent data which indicate considerable variability in platelet phenotype which accounts for differences in platelet surface receptor function, count and reactivity with subsequent thrombotic events. The identification of a contribution by platelet glycoproteins polymorphism to Ischemic cerebrovascular stroke which is a multifactorial, polygenic pathological process is challenging.

Back to Top | Article Outline

Aims:

Assessment of the genetic platelet glycoprotein (GPIIb/IIIa) polymorphism, as a genetic risk factor in ischemic cerebrovascular stroke patients in Ismailia, Egypt.

Back to Top | Article Outline

Methods:

Study population included: Fifty adult ischemic cerebrovascular stroke patients (acute, recent or old) and fifty-healthy control group matching the patients group. Hematological and biochemical; Molecular assessment included DNA extraction and purification using micro-centrifugation technique were done. DNA amplification was carried out by PCR-RFLP technique. Genotypic determination of the platelet GPIIb/IIIa genotypes was carried out using agarose gel electrophoresis of the PCR products after endonuclease restriction with enzyme Msp-I.

Back to Top | Article Outline

Results:

Platelet glycoprotein GP IIIa (PlA2/A2) genotypic distribution showed a statistically significant difference in ischemic cerebrovascular stroke patients in comparison with the healthy matched controls (the control group: GPIIIa (PlA1/PlA1: homozygous) 82%, GPIIIa (PlA1/PlA2 heterozygous) 16%, GPIIIa (PlA1/PlA1), and GPIIIa (PlA2/PlA2 homozygous) 2%. While the patients group: GPIIIa (PlA1/PlA1: homozygous) 58%, GPIIIa (PlA1/PlA2 heterozygous) 32%, GPIIIa (PlA1/PlA1), and GPIIIa (PlA2/PlA2 homozygous) 10%. There were statistically significant differences in between study groups regarding Platelet GP IIIa (PlA2/A2)genotypes, smoking, hypertension, diabetes, and dyslipidaemia; dyslipidaemia showed the highest odds ratio of all the risk factors.

Figure

Figure

Back to Top | Article Outline

Summary/Conclusion:

Conclusions: In this population, the genetic platelet glycoprotein GPIIIa (PlA1/PlA2) polymorphism is a reliable and significant predictor biomarker in the prediction of ischemic cerebrovascular stroke and the platelet glycoprotein GPIIIa (PlA2/PlA2) mutant allele was identified as a risk factor ischemic cerebrovascular stroke.

Copyright © 2019 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the European Hematology Association.